Literature DB >> 1636163

Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues.

M Nakamura1, H Konno, T Tanaka, Y Maruo, N Nishino, K Aoki, S Baba, S Sakaguchi, Y Takada, A Takada.   

Abstract

The concentrations of urinary type plasminogen activator (u-PA), plasminogen activator inhibitor 1 (PAI-1), and PAI-2 were measured in gastric cancer tissues and adjacent healthy mucosal tissues. Levels of u-PA, PAI-1 and PAI-2 were higher in cancer than in control tissues. PAI-1 levels were higher together with the progression of cancer however there were no differences in u-PA or PAI-2 levels. Tumors with higher PAI-1 and lower PAI-2 levels tend to metastasize to remote lymph nodes. When the numbers of involved lymph nodes were analyzed, tumors with the large number of metastatic lymph nodes showed higher PAI-1 and lower PAI-2 level. No difference was shown in u-PA levels among these groups. These tendencies were more significant in patients with progressed gastric cancer. These results suggest that tumor with higher PAI-2 levels tend to localize or have less tendency to metastasize to lymph nodes. On the other hand PAI-1 was generally higher in tumor with invasion into nearby tissue or with nodal metastasis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1636163     DOI: 10.1016/0049-3848(92)90110-v

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  13 in total

1.  Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.

Authors:  H Ito; Y Yonemura; H Fujita; K Tsuchihara; T Kawamura; N Nojima; T Fujimura; H Nose; Y Endo; T Sasaki
Journal:  Virchows Arch       Date:  1996-02       Impact factor: 4.064

2.  Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.

Authors:  M Plebani; L Herszènyi; P Carraro; M De Paoli; G Roveroni; R Cardin; Z Tulassay; R Naccarato; F Farinati
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

3.  Silencing of integrated human papillomavirus type 18 oncogene transcription in cells expressing SerpinB2.

Authors:  Grant A Darnell; Toni M Antalis; Barbara R Rose; Andreas Suhrbier
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Gastrin stimulates expression of plasminogen activator inhibitor-1 in gastric epithelial cells.

Authors:  Kristin G Nørsett; Islay Steele; Cedric Duval; Stephen J Sammut; Senthil V M Murugesan; Susan Kenny; Lucille Rainbow; Rod Dimaline; Graham J Dockray; D Mark Pritchard; Andrea Varro
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-12-30       Impact factor: 4.052

5.  Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.

Authors:  T J de Vries; P H Quax; M Denijn; K N Verrijp; J H Verheijen; H W Verspaget; U H Weidle; D J Ruiter; G N van Muijen
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

6.  Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif.

Authors:  Grant A Darnell; Toni M Antalis; Ricky W Johnstone; Brett W Stringer; Steven M Ogbourne; David Harrich; Andreas Suhrbier
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

7.  Decreased expression of SERPINB1 correlates with tumor invasion and poor prognosis in hepatocellular carcinoma.

Authors:  Xiaopeng Cui; Yanhua Liu; Chunhua Wan; Cuihua Lu; Jing Cai; Song He; Tingting Ni; Junya Zhu; Lixian Wei; Yixin Zhang; Haixin Qian
Journal:  J Mol Histol       Date:  2013-10-09       Impact factor: 2.611

Review 8.  Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression.

Authors:  M Yamamoto; R Sawaya; S Mohanam; V H Rao; J M Bruner; G L Nicolson; K Ohshima; J S Rao
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

9.  Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.

Authors:  S Ganesh; C F Sier; M M Heerding; J H van Krieken; G Griffioen; K Welvaart; C J van de Velde; J H Verheijen; C B Lamers; H W Verspaget
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions.

Authors:  Song Yi Bae; Hyen Joo Park; Ji-Young Hong; Hye-Jung Lee; Sang Kook Lee
Journal:  Sci Rep       Date:  2016-08-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.